Voice of China Archives - Page 3 of 6

Dr. Weiming Tang: Exploring Crowdsourced Partner Notification Services for High-Risk HIV Populations

By Mourabit Halima 2024.01.14

In China, the transmission of HIV (Human Immunodeficiency Virus) primarily occurs through sexual transmission. [1] Partner notification services help those who are HIV-positive inform their sexual partners of their infection status and guide these partners to undergo HIV testing. [2] Thus, it is crucial for identifying newly infected individuals and preventing further HIV transmission. [3] Currently, the partner notification rate among key populations in China (e.g., men who have sex with men) is low. [4] To increase the acceptance of partner notification services (HIV PS) among men who have sex with men living with HIV (MLWH), the Dermatology Hospital of Southern Medical University collaborated with the China Program Office of the University of North Carolina to establish the Saith Project. This initiative aims to develop a crowdsourced intervention scheme through a series of crowdsourcing competitions in partnership with community organizations.

Dr. Yanhua Ding’s Team: Clinical Research on HBV CAM New Drugs and NAFLD Prediction Model Selected for Conference Presentation

By Mourabit Halima 2024.01.02

Dr. Yanhua Ding's Team: Clinical Research on HBV CAM New Drugs and NAFLD Prediction Model Selected for Conference Presentation Yanhua Ding practices in Changchun, China. Ding and is rated as an Experienced expert by MediFind in the treatment of Arthritis. They are also highly rated in 3 other conditions, according to our data. Their top areas of expertise are Hepatitis, Hepatitis B, Hepatitis C, and Type 2 Diabetes (T2D).

Dr. Jinlin Hou and Dr. Fan Rong’s Team: The Joint Application of aMAP Score and LSM Provides a New Strategy for Liver Fibrosis Assessment in Untreated

By Mourabit Halima 2024.01.02

The assessment of liver fibrosis in patients with chronic hepatitis B (CHB) is of significant importance for initiating antiviral treatment and evaluating treatment efficacy. Serum models represented by Fibrosis-4 index (FIB-4) and aspartate transaminase-to-platelet ratio index (APRI) exhibit inconsistent diagnostic performance for liver fibrosis in different study populations. Moreover, there is controversy regarding whether the dynamic changes in liver stiffness measurement (LSM) during antiviral treatment can predict fibrosis reversal. Therefore, new models or indicators are still needed for fibrosis assessment in CHB patients before and after antiviral treatment.

AASLD Interview | Professor Fengmin Lu: Exploring Interferon Cure Advantages in Chronic Hepatitis B, Delving into Mechanisms to Guide New Drug Development

By Mourabit Halima 2023.12.25

At the just-concluded Annual Summit of Hepatology, the American Association for the Study of Liver Diseases (AASLD2023), Professor Fengmin Lu's team from Peking University presented three contributions (1 oral presentation and 2 posters), focusing on the mechanisms related to chronic HBV infection. Their research revealed populations benefiting from interferon therapy in chronic Hepatitis B (CHB) and explored potential new targets for curing. "Hepatology Digest" has specially invited Professor Fengmin Lu to interpret the research findings, their significance and implications for future scientific research or clinical practice, and to envision the prospects for functional cure among the CHB population in our country.

Professor Chen Yaokai: Factors Affecting the Prognosis of HIV Patients with Talaromyces Marneffei Co-Infection Treated with Amphotericin B Deoxycholate

By Mourabit Halima 2023.12.08

Talaromyces marneffei (TM) is a thermal dimorphic fungus that can cause systemic fungal infections in humans. This fungal infection is common in immunocompromised individuals and is one of the leading causes of death among HIV/AIDS patients in Southeast Asia and South Asia. At the 19th European AIDS Conference (EACS) held from October 18 to 21, 2023, Professor Chen Yaokai and his team from the Chongqing Public Health Medical Treatment Center presented a research report titled "Severe Anemia, Severe Leukopenia, and Severe Thrombocytopenia in HIV-Related Talaromyces Marneffei Infection Induced by Amphotericin B Deoxycholate: A Secondary Analysis of a Prospective Multicenter Cohort Study." This study contributes to global efforts to combat the HIV epidemic and co-infections by presenting findings from China. Below is a summary of their research.

Professor Chen Yaokai: A Systematic Review and Meta-Analysis of Raltegravir Treatment for HIV-Positive Pregnant Women

By Mourabit Halima 2023.12.08

HIV can be transmitted through bodily fluids such as blood, breast milk, semen, and vaginal secretions. Pregnant women who are infected with HIV should receive antiretroviral therapy (ART) as soon as possible to protect their own health and reduce the risk of transmitting HIV to their unborn child. At the recent 19th European AIDS Conference (EACS 2023), Professor Chen Yaokai and his team from the Chongqing Public Health Medical Treatment Center presented a report titled "The Effectiveness of Raltegravir in Virological Suppression of HIV-Positive Pregnant Women at Delivery: A Systematic Review and Meta-Analysis." The study analyzed the effectiveness of Raltegravir treatment for pregnant women with HIV, initiated at different stages of pregnancy, in achieving virological suppression at the time of delivery, and conducted subgroup analyses for treated and untreated pregnant women.

Professor Zhu Biao: Impact of Single-Tablet HIV Medications B/F/TAF and E/C/F/TAF on Lipid Metabolism

By Mourabit Halima 2023.12.08

AIDS remains a significant global health concern, but recent advancements in medical technology have shifted the treatment of HIV-infected individuals toward a chronic disease management approach. Ensuring treatment safety and adherence is a critical challenge within this context. Currently, two single-tablet regimens, Biktarvy (B/F/TAF) and Descovy (E/C/F/TAF), are widely used globally, including in China, for managing HIV infections. These regimens not only effectively suppress the virus but also offer good safety and adherence rates. In recent years, concerns have arisen about complications related to HIV infection, particularly the increased risk of cardiovascular diseases (CVD) associated with long-term antiretroviral drug use. This risk significantly affects the life expectancy and long-term health of HIV-infected individuals. From October 18 to 20, 2023, the 19th European AIDS Conference (EACS 2023) was held in Warsaw, Poland. During the conference, a clinical study led by Professor Zhu Biao from the First Affiliated Hospital of Zhejiang University School of Medicine was featured as a poster presentation (Abstract No. 551). This study suggests that compared to E/C/F/TAF, B/F/TAF has a milder impact on lipid metabolism and is associated with a reduced risk of CVD.

Dr. Chun-rong Ju: Lung Transplant Recipients Receive Prolonged Contezolid Treatment for Nocardia InfectionDr. Chun-rong Ju: Lung Transplant Recipients

By Peter W. PENG 2023.11.28

Nocardia is a conditional pathogen, and infections are common in immunocompromised populations such as organ transplant recipients. Professor Chunrong Ju and her team at the First Affiliated Hospital of Guangzhou Medical University's Respiratory and Critical Care Department and Transplant Department previously reported cases of Nocardia infection in lung transplant recipients (LTR) among the East Asian population [1,2]. During the 2023 IDWeek congress, Dr. Chun-rong Ju further presented the clinical outcomes of 18 LTR Nocardia infection patients who received treatment with the novel oxazolidinone-class drugs Linezolid or Contezolid. The results indicated that these novel oxazolidinone drugs were effective during prolonged anti-infection therapy in such patients and had fewer toxic side effects, including bone marrow suppression [3].

Youth Forum of APACC 2023 | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

By Peter W. PENG 2023.10.23

Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.

Dr. Linghua Li: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients

By Peter W. PENG 2023.10.22

The 8th Asia-Pacific AIDS and Co-infection Conference (APACC 2023) was held in Singapore from June 8 to 10, 2023. During this conference, an oral presentation (Abstract #9) conducted by Dr. Linghua Li's team from the Eighth Affiliated Hospital, Guangzhou Medical University, China, attracted significant attention. Dr. Li 's team, based on the latest findings from a large cohort study, revealed that the hepatitis B surface antigen (HBsAg) clearance rate in HIV/HBV co-infected individuals who received long-term combination antiretroviral therapy (cART) could reach 8.1%. Furthermore, the research results unveiled that the main influencing factors for HBsAg clearance in HIV/HBV co-infected individuals included low baseline HBsAg levels, HBV genotype B, and a more than two-fold increase in ALT within six months of treatment.